Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2021 Mar 4

PMID 33658809

Citations 3

Authors

Ana Paula de Torres Santos

Vanessa Cristina Martins Silva

Maria Cassia Mendes-Correa

Marcilio Figueiredo Lemos

Fernanda de Mello Malta

Rubia Anita Ferraz Santana

Gregorio Tadeu Fernando Dastoli

Vanessa Fusco Duarte de Castro

Joao Renato Rebello Pinho

Regina Celia Moreira

Affiliations

Soon will be listed here.

Abstract

Purpose: Globally, it is estimated that 71 million people are chronically infected with hepatitis C, and 10-20% of these will develop cirrhosis and hepatocellular carcinoma. The development of new direct-acting antiviral (DAA) drugs has contributed to sustained virological response (SVR), eliminating the infection and achieving cure of chronic hepatitis C. However, treated patients can develop HCV resistance to DAAs, which can contribute to the failure of treatment. Here, we aimed to evaluate the prevalence and specific pattern of NS5A and NS5B resistance-associated substitutions (RAS) in samples from patients chronically infected with HCV genotype 3a at a public health laboratory, Instituto Adolfo Lutz, São Paulo, Brazil.

Patients And Methods: Serum samples from the enrolled individuals were submitted to "in-house" polymerase chain reaction amplification of NS5A and NS5B non-structural protein genes, which were then sequenced by Sanger method.

Results: A total of 170 and 190 samples were amplified and analyzed for NS5A and NS5B, respectively. For NS5A, 20 (12.0%) samples showed some important RAS; 16 (9.0%) showed some type of substitution and 134 (79.0%) showed no polymorphism. No sample showed any RAS for NS5B.

Conclusion: This study found important RAS in samples from naïve chronic HCV patients in some areas from São Paulo. The most prevalent were A62S, A30K, and Y93H, which could indicate an increase in resistance to some DAAs used in HCV treatment.

Citing Articles

Hepatitis A, B and C prevalence among transgender women and travestis in five Brazilian capitals between 2019-2021.

Moreira R, de Sousa Mascena Veras M, Amianti C, McCartney D, Silva V, Lemos M Rev Bras Epidemiol. 2024; 27Suppl 1(Suppl 1):e240005.supl.1.

PMID: 39166577 PMC: 11338541. DOI: 10.1590/1980-549720240005.supl.1.

Hepatitis C virus prevalence among men who have sex with men: a cross-sectional study in 12 Brazilian cities.

Silva V, Kerr L, Kendall C, Mota R, Guimaraes M, Leal A BMC Infect Dis. 2023; 23(1):705.

PMID: 37858036 PMC: 10588169. DOI: 10.1186/s12879-023-08690-2.

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.

Santos A, Silva V, Mendes-Correa M, Lemos M, de Mello Malta F, Santana R Rev Inst Med Trop Sao Paulo. 2022; 64:e61.

PMID: 36197422 PMC: 9528309. DOI: 10.1590/S1678-9946202264061.

References

Costa V, Brandao-Mello C, Nunes E, Dos Santos Silva P, de Souza Rodrigues L, Lampe E . Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. PLoS One. 2019; 14(5):e0216327. PMC: 6504041. DOI: 10.1371/journal.pone.0216327. View

Heffernan A, Cooke G, Nayagam S, Thursz M, Hallett T . Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019; 393(10178):1319-1329. PMC: 6484702. DOI: 10.1016/S0140-6736(18)32277-3. View

Sharafi H, Alavian S . Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?. World J Hepatol. 2018; 10(9):543-548. PMC: 6177567. DOI: 10.4254/wjh.v10.i9.543. View

Lawitz E, Dvory-Sobol H, Doehle B, Worth A, McNally J, Brainard D . Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016; 60(9):5368-78. PMC: 4997818. DOI: 10.1128/AAC.00763-16. View

Hezode C, Reau N, Svarovskaia E, Doehle B, Shanmugam R, Dvory-Sobol H . Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2017; 68(5):895-903. DOI: 10.1016/j.jhep.2017.11.032. View

Ng T, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J . Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017; 61(5). PMC: 5404558. DOI: 10.1128/AAC.02558-16. View

Sarrazin C . The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2015; 64(2):486-504. DOI: 10.1016/j.jhep.2015.09.011. View

Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U . Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses. 2017; 9(8). PMC: 5580469. DOI: 10.3390/v9080212. View

SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-7. PMC: 431765. DOI: 10.1073/pnas.74.12.5463. View

10.

Scheel T, Rice C . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013; 19(7):837-49. PMC: 3984536. DOI: 10.1038/nm.3248. View

11.

Kim C, Chang K . Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013; 19(1):17-25. PMC: 3622851. DOI: 10.3350/cmh.2013.19.1.17. View

12.

Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C . Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection. 2018; 46(6):761-783. DOI: 10.1007/s15010-018-1188-3. View

13.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

14.

Wang C, Valera L, Jia L, Kirk M, Gao M, Fridell R . In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother. 2012; 57(1):611-3. PMC: 3535966. DOI: 10.1128/AAC.01874-12. View

15.

Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F . Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013; 57(1):13-8. DOI: 10.1016/j.jcv.2012.12.020. View

16.

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng T, Reisch T . Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153825. DOI: 10.1128/AAC.01249-18. View

17.

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme A, Rockstroh J . Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016; 26(6):408-434. DOI: 10.1002/rmv.1895. View

18.

Vermehren J, Sarrazin C . The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012; 26(4):487-503. DOI: 10.1016/j.bpg.2012.09.011. View

19.

Sorbo M, Cento V, Di Maio V, Howe A, Garcia F, Perno C . Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat. 2018; 37:17-39. DOI: 10.1016/j.drup.2018.01.004. View

20.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View